New application of AZD-9291 in inhibiting infection of alphaviruses such as ONNV

Abstract

The invention discloses an application of a marketed drug AZD-9291 (Osimertinib, osimertinib) in resisting infection of alphaviruses such as ONNV (O'nyong-nyong virus) and the like, and relates to the technical field of drugs, in particular to an application of the drug AZD-9291 (Osimertinib, osimertinib) in resisting infection of alphaviruses such as ONNV (O'nyong-nyong virus) and the like. Experimental results show that the AZD-9291 can be used for effectively inhibiting the infection of four pseudovirus particles, namely ONNV (ONNV), CHIKV (Chikungunya virus), EEEV (Eastern equine encephalitis virus) and SFV (Semliki Forest Virus), on host cells, and the AZD-9291 can be used for effectively inhibiting the infection of the four pseudovirus particles, namely ONNV, CHIKV, Chikungunya virus, EEEV, Eastern equine encephalitis virus, and SFV (Semliki Forest Virus, forest encephalitis virus). The CC50 of AZD-9291 in HEK293T cells is determined to be 53.3 [mu] M, then the inhibition effect of the compound on ONNV pseudoviruses is determined, the IC50 of the compound is 1.41 [mu] M, and meanwhile, the compound is found to have no inhibition effect on infection of rVSV [delta] G-G control pseudoviruses. Subsequently, the inhibition effect of AZD-9291 on other alphaviruses such as CHIKV, EEEV and SFV in HEK293T cells is determined, and the IC50 (half maximal inhibitory concentration) of AZD-9291 is 3.74 mu M, 5.18 mu M and 3.47 mu M respectively. The research proves that AZD-9291 can be used as a broad-spectrum candidate drug for inhibiting infection of alphaviruses such as ONNV, CHIKV and the like, and new application and new prospect of AZD-9291 as a clinical alphavirus infection treatment drug and preparation are shown.

Images